PharmaMar and Chugai Pharmaceutical enter into a license and commercialization agreement for PM1183 in Japan. PharmaMar has announced the signing of an exclusive license, development and commercialization agreement with Chugai Pharmaceutical Co. Ltd. for its third marine-derived anti-cancer drug PM1183 (lurbinectedin) in Japan. Under the terms of the agreement, PharmaMar will receive an upfront payment of €30 million ($31.3…